Featured Research

from universities, journals, and other organizations

Hospital reduces incidence of hospital-associated C. difficile by 70 percent

Date:
June 20, 2013
Source:
Lifespan
Summary:
Rhode Island Hospital has reduced the incidence of hospital-associated Clostridium difficile (C. difficile) infections by 70 percent and reduced annual associated mortality in patients with hospital-associated C. difficile by 64 percent through successive implementation of five rigorous interventions. A major cause of morbidity and mortality in the US, C. difficile can cause life-threatening infections that occur most frequently in patients who have received antibiotic therapy.

Rhode Island Hospital has reduced the incidence of hospital-associated Clostridium difficile (C. difficile) infections by 70 percent and reduced annual associated mortality in patients with hospital-associated C. difficile by 64 percent through successive implementation of five rigorous interventions , as reported in the July 2013 issue of The Joint Commission Journal on Quality and Patient Safety.

Clostridium difficile is a toxin-producing bacterium that lives in the colon. A major cause of morbidity and mortality in the U.S., it can cause life-threatening infections that occur most frequently in patients who have received antibiotic therapy. Unlike other bacteria causing healthcare-related infections, C. difficile can be difficult to clear from the environment due to its ability to survive for prolonged periods of time as spores.

"Hospital-acquired infections are a major concern for hospitals across the country and C. difficile is among the most dangerous," says principal investigator Leonard Mermel, D.O., medical director of the department of epidemiology and infection control at Rhode Island Hospital. "The risks to patients are enormous, as is the excess associated hospital cost."

Mermel et al. note that from 2000 to 2009, discharge diagnoses from U.S. hospitals that included C. difficile increased from 139,000 to 336,600 -- a 242 percent increase. Similarly, the yearly national excess hospital cost associated with hospital-onset C. difficile is estimated to be upward of $1.3 billion.

To measure and reduce the incidence of hospital-acquired C. difficile, Mermel and his colleagues implemented a multi-step process based on a risk assessment: develop and implement a C. difficile infection control plan; monitor additional data sets, including associated mortality and morbidity as measured by C. difficile-related colectomies; improve sensitivity of C. difficile toxin detection in stool specimens to reduce false-negative results; and enhanced environmental cleaning of patient rooms and equipment.

Researchers monitored the number of C. difficile infections per 1,000 hospital discharges from the second quarter of 2006 to the third quarter of 2012, and found that hospital-associated C. difficile infections were reduced from a peak of 12.2 per 1,000 to 3.6 per 1,000 discharges. Additionally, the mortality in patients associated with this infection was reduced from a peak of 52 in 2006 to 19 in 2011, and by the end of the third quarter of 2012, that number was down to 13.

"This is a significant, hospital-wide effort involving the support of hospital administration, the department of epidemiology and infection control, nursing, medicine, surgery, pathology, pharmacy, environmental services and the microbiology lab. It is truly a multi-disciplinary effort to make the hospital safer for our patients, their families and our staff." Mermel said.

"By working together to better monitor those patients at risk, enhance the cleaning of patient rooms and equipment, and to use contact precautions as appropriate, we were able to significantly reduce the risk of this virulent infection and ultimately to provide better, safer patient care."

According to the Centers for Disease Control and Prevention, 94 percent of C. difficile infections are related to receiving medical care, and hospital stays from this infection tripled in the last decade, posing a patient safety threat especially harmful to older Americans. The infection causes diarrhea linked to 14,000 American deaths each year.


Story Source:

The above story is based on materials provided by Lifespan. Note: Materials may be edited for content and length.


Cite This Page:

Lifespan. "Hospital reduces incidence of hospital-associated C. difficile by 70 percent." ScienceDaily. ScienceDaily, 20 June 2013. <www.sciencedaily.com/releases/2013/06/130620111234.htm>.
Lifespan. (2013, June 20). Hospital reduces incidence of hospital-associated C. difficile by 70 percent. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/06/130620111234.htm
Lifespan. "Hospital reduces incidence of hospital-associated C. difficile by 70 percent." ScienceDaily. www.sciencedaily.com/releases/2013/06/130620111234.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins